Considerations in the Design of Hyperinsulinemic-Euglycemic Clamps in the Conscious Mouse
http://www.100md.com
糖尿病学杂志 2006年第2期
the Vanderbilt-NIDDK (National Institutes of Diabetes and Digestive and Kidney Diseases) Mouse Metabolic Phenotyping Center, Vanderbilt University School of Medicine, Nashville, Tennessee
Key Words: GIR, glucose infusion rate
ABSTRACT
Despite increased use of the hyperinsulinemic-euglycemic clamp to study insulin action in mice, the effects of experimental parameters on the results obtained have not been addressed. In our studies, we determined the influences of sampling sites, fasting duration, and insulin delivery on results obtained from clamps in conscious mice. Carotid artery and jugular vein catheters were implanted in C57BL/6J mice (n = 6eC10/group) fed a normal diet for sampling and infusions. After a 5-day recovery period, mice underwent a 120-min clamp (2.5-mU · kgeC1 · mineC1 insulin infusion; 120eC130 mg/dl glucose) while receiving [3-3H]glucose to determine glucose appearance (endoRa) and disappearance (Rd). Sampling large volumes (100 e蘬) from the cut tail resulted in elevated catecholamines and basal glucose compared with artery sampling. Catecholamines were not elevated when taking small samples ( 5 e蘬) from the cut tail. Overnight (18-h) fasting resulted in greater loss of total body, lean, and fat masses and hepatic glycogen but resulted in enhanced insulin sensitivity compared with 5-h fasting. Compared with a 16-mU/kg insulin prime, a 300-mU/kg prime resulted in hepatic insulin resistance and slower acquisition of steady-state glucose infusion rates (GIR) after a 5-h fast. The steady-state GIR was expedited after the 300-mU/kg prime in 18-heCfasted mice. The GIR and Rd rose with increasing insulin infusions (0.8, 2.5, 4, and 20 mU · kgeC1 · mineC1), but endoRa was fully suppressed with doses higher than 0.8 mU · kgeC1 · mineC1. Thus, common variations in experimental factors yield different results and should be considered in designing and interpreting clamps.
The hyperinsulinemic-euglycemic clamp, or insulin clamp, has been referred to as the "gold standard" for measuring insulin sensitivity in vivo. In this procedure, insulin is administered to raise the insulin concentration while glucose is infused to maintain euglycemia. The glucose infusion rate (GIR) needed to maintain euglycemia is a reflection of insulin action. When radioisotopes, such as [3H]glucose, are infused in conjunction with an insulin clamp, endogenous glucose appearance (endoRa) and glucose disappearance (Rd) can be measured, allowing for the differentiation between hepatic and peripheral insulin sensitivity. Given the prominent role of insulin resistance in the development of various metabolic disorders, the insulin clamp is a useful tool in basic and clinical research.
With the development of transgenic technologies in the mouse, the miniaturization of the insulin clamp for use in this animal has been an important advancement. It is thus surprising that in the >10 years since its first use in the mouse, there has been no assessment of the insulin clamp methodology in this animal. A literature search for the period 2003eC2004 found 25 publications using the insulin clamp in conscious mice (1eC25). In these studies, the various protocols that were used differed in blood sampling sites, insulin and tracer infusion methods, and fasting duration. For example, 44% of these studies described the sampling site as the cut tail, whereas 12% used an arterial catheter. The remaining 44% did not indicate or reference a study indicating a sampling site. In a similar finding, 48% of these studies used mice fasted overnight (for 16eC18 h), 40% used mice fasted for 5eC6 h, and 12% used other fasting durations. Finally, 40% of these clamp studies were performed without a priming dose of insulin, whereas 48% administered a prime equal to the total insulin infused at a constant rate. The remaining 12% used priming doses ranging between these two extremes. Given this diversity of approaches, it is crucial to determine how experimental parameters influence clamp studies in the mouse to better compare results obtained by different investigators. Using common clamp protocols as guidelines (18,26eC28), three parameters were compared: blood sampling sites, fasting duration, and insulin infusion (prime and constant rate) methods.
RESEARCH DESIGN AND METHODS
All procedures were approved by the Vanderbilt Animal Care and Use Committee. Male, 8-week-old C57BL/6J mice (The Jackson Laboratories, Bar Harbor, ME) were obtained and placed on a sterilized rodent diet (Harlan Teklad LM-485, #7912; Harlan Teklad, Madison, WI) for 1 week before surgery. Animals were housed under controlled temperature (23°C) and lighting (12 h light:12 h dark) conditions with free access to water and food.
Mice (n = 95) were catheterized at least 5 days before the experiments (29) after being anesthetized with sodium pentobarbital (70 mg/kg body wt). The left common carotid artery was catheterized for sampling using a two-part catheter consisting of PE-10 (inserted into the artery) and silastic (0.025 outer diameter [OD]). The right jugular vein was catheterized for infusions with a silastic catheter (0.025 OD). The free catheter ends were tunneled under the skin to the back of the neck and attached via stainless steel connectors to tubing made of Micro-Renathane (0.033 OD); the tubing was externalized and sealed with stainless steel plugs. In a subset of mice, only a jugular vein catheter was implanted (see COMPARISON OF SAMPLING SITES [below]). Lines were flushed daily with 50 e蘬 saline containing 200 units/ml heparin and 5 mg/ml ampicillin. Animals were individually housed after surgery, and their body weight was recorded daily. Animals not within 10% of their presurgery weight by postsurgery day 5 were excluded from the study.
Hyperinsulinemic-euglycemic clamps.
This section describes the general protocol used in all experiments. Modifications are described where appropriate in the following sections.
After being fasted for 5 or 18 h, mice were studied in individual 1.4-l plastic containers with bedding or a restrainer (552-BSRR; Plas-Labs, Lansing, MI) for cut tail sampling. The protocol consisted of a 120-min tracer equilibration period (t = eC120 to 0 min) beginning at 8:00 A.M. followed by a 120-min experimental period (t = 0 to 120 min) beginning at 10:00 A.M. A blood sample (5 e蘬) was obtained at t = eC120 min to determine initial glucose levels (HemoCue Meter; HemoCue, Lake Forest, CA). A 5-e藽i bolus of [3-3H]glucose purified by high-performance liquid chromatography was given at t = eC120 min followed by a 0.05 e藽i/ min infusion for 2 h. At t = eC5 min, a blood sample (100 e蘬) was taken for the assessment of basal glucose and insulin levels and glucose turnover. The insulin clamp was begun at t = 0 min with a primed-continuous infusion of human insulin (16 or 300 mU/kg bolus followed by 2.5 mU · kgeC1 · mineC1; Humulin R; Eli Lilly, Indianapolis, IN). The [3-3H]glucose infusion was increased to 0.1 e藽i/ min for the remainder of the experiment to minimize changes in specific activity from the equilibration period. Specific activity for individual time points did not vary by >15% from the average specific activity during the last 40 min of the clamp, and the slope of specific activity over time was not significantly different from zero. Euglycemia (120eC130 mg/dl) was maintained during clamps by measuring blood glucose every 10 min starting at t = 0 min and infusing 20% dextrose as necessary. Blood samples (60eC200 e蘬) were taken every 10 min from t = 80 to 120 min and processed to determine glucose specific activity. Clamp insulin levels were determined from samples obtained at t = 100 and 120 min. Additional samples (100 e蘬) were taken at t = eC120, eC5, and 120 min for the assessment of catecholamines. Mice received saline-washed erythrocytes from donors throughout the experimental period (5eC6 e蘬/min) to prevent a fall of >5% hematocrit.
Comparison of sampling sites.
In these studies, 18-heCfasted mice were compared using a 300-mU/kg insulin prime. For cut tail sampling, mice were surgically prepared with only a jugular vein catheter. The tip of the tail (1 cm) was cut off at t = eC120 min in restrained animals, and blood was sampled by squeezing the tail from base to tip. Samples obtained from the cut tail are composed of arterial and venous blood as well as lymph fluid. For arterial sampling, the externalized catheters were tethered to a stainless steel swivel (Instech Laboratories, Plymouth Meeting, PA) with Micro-Renathane tubing. This approach eliminated the need for restraining or any further handling of the mouse. In some studies, samples were obtained from both the cut tail and an arterial catheter in restrained mice.
Comparison of fasting duration.
Arterial catheters were used for sampling in these experiments. For the 5-heCfasting studies, food was removed at 5:00 A.M. on the day of the experiment, and for the 18-heCfasting studies, food was removed at 4:00 P.M. on the day before the experiment. Thus, all insulin infusions began at 10:00 A.M. Clamps followed a 16-mU/kg insulin prime. Body composition was determined in 5-heCand 18-heCfasted mice using a mq10 NMR analyzer (Bruker Optics, The Woodlands, TX). Liver and gastrocnemius muscle glycogen was determined as previously described (30). Food consumption was determined using a precision scale and continuous computer monitoring.
Comparison of insulin delivery methods.
Arterial catheters were used for sampling in these experiments. In one set of experiments, the insulin prime was 16 mU/kg. This dose was calculated as the amount of insulin required to fill the distribution volume (Vd) to the target clamp concentration (80 e蘒/ml). Insulin Vd was assumed to be 20% of body weight, an approximation based on the observed insulin Vd in humans (15.6% body wt) and the approximate plasma and interstitial fluid volume (25% body wt) (31). In a second set of experiments, the insulin prime was 300 mU/kg (1eC3). This is equal to the amount of insulin administered during the 120-min infusion. Assuming equal insulin clearance and Vd, the theoretical peak plasma insulin concentrations were 80 and 1,600 e蘒/ml with the 16- and 300-mU/kg boluses, respectively. Clamps were performed on 5-heCand 18-heCfasted mice.
For the insulin dose-response studies, clamps were performed on 5-heCfasted mice using constant insulin infusions of 0.8, 2.5, 4, or 20 mU · kgeC1 · mineC1.
Processing of plasma samples.
Plasma for [3-3H]glucose determinations was deproteinized with Ba(OH)2 and ZnSO4. For each sample, an aliquot of the supernatant was counted directly and another was dried to remove 3H2O. Plasma 3H2O was determined as the difference between dried and undried samples. Immunoreactive insulin (32) and catecholamines (33) were determined as previously described.
Calculations.
Ra and Rd were determined using Steele’s noneCsteady-state equations (34). Endogenous glucose production (endoRa, given as milligrams per kilogram per minute) was determined by subtracting the GIR from total Ra. Glycolytic rates were estimated from the increment per unit of time of 3H2O multiplied by the estimated body water divided by [3-3H]glucose specific activity. 3H2O appearance was determined by linear regression of the measurements at t = 80 to 120 min. Body water was assumed as 60% of body weight (35).
Statistical analysis.
Data are presented as means ± SE. Differences between groups were determined by two-way ANOVA followed by Tukey’s post hoc tests or by the t test, as appropriate. The significance level was P < 0.05.
RESULTS
Comparison of sampling sites.
Of the insulin clamp studies in the mouse published in 2003eC2004, 56% specified how blood was obtained. In most of these (80%), samples were obtained from the cut tail. We compared insulin clamps where the blood was obtained from the cut tail with those in which blood was obtained from an indwelling catheter. As shown in Fig. 1, epinephrine and norepinephrine were elevated in cut taileCcompared with artery-sampled mice throughout the study. This is consistent with previous reports of catecholamines in mice where blood was acquired from the cut tail (36). These elevated catecholamines were not due to mouse restraint or tail cutting. Restrained mice that had their tails cut off but were sampled from the artery showed catecholamine levels similar to those in unrestrained, artery-sampled mice (Fig. 1). The elevated catecholamines in the cut taileCsampled group were due to stress from the acquisition of the blood volume (100 e蘬) required for hormone assessment, which necessitates more manual squeezing of the tail than for smaller blood volumes. In mice sampled from both the artery and cut tail (Fig. 1), the larger volume of blood needed for catecholamine analysis was obtained from the artery, thus requiring less handling than when large samples were taken from the cut tail. The blood volume taken from the cut tail in these mice was 5 e蘬.
Basal glucose was significantly higher in cut taileCcompared with artery-sampled mice (Fig. 2A). This was not due to differences in arterial and cut tail glucose, because concentrations were similar in blood from both sites (Fig. 2A, inset). During clamps, blood glucose was similar in both groups (Fig. 2A). Because of the higher basal glucose in cut taileCsampled mice, the GIR required to clamp glucose in these mice was significantly lower for the first 20 min of the clamp compared with artery-sampled mice (Fig. 2B). The GIR was not different in cut taileCcompared with artery-sampled mice during the remainder of the experiment (Fig. 2B). Clamp endoRa was significantly higher in cut taileCcompared with artery-sampled mice (Table 1). However, clamp Rd was also significantly higher in cut taileCcompared with artery-sampled mice (Table 1), thus maintaining similar GIR between groups during the clamp.
Comparison of fasting duration.
The effects of fasting duration on the results from insulin clamps were investigated given the equal distribution of recent studies using 5-heCor 18-heCfasted mice. Because mice are primarily nocturnal feeders, an 18-h overnight fast represents a proportionately larger deprivation of calories. Mice consume 30% of their daily food intake during the daytime (Fig. 3). Thus, mice are already in a low-consumption mode when an 18-h fast is started (27). The subsequent overnight fast in our studies resulted in a significant loss of body weight (5 vs. 16% in 5-heCand 18-heCfasted mice, respectively) due to a reduction in fat and muscle tissue (Table 2). Overnight fasting also resulted in significantly lower hepatic, but not muscle, glycogen content (Table 2).
Basal glucose and insulin were lower in 18-heCcompared with 5-heCfasted mice (Table 3). Clamps were performed using a 16-mU/kg insulin prime, and samples were obtained from an arterial catheter. Clamp insulin levels were not different between groups (Table 4). Blood glucose fell in 18-heCcompared with 5-heCfasted mice during the first 40 min of the clamp, after which glucose was similar in both groups (Fig. 4A). The lower initial glucose levels and difficulty in maintaining euglycemia in 18-heCfasted mice was due to a delay in compensating for the increased insulin sensitivity in these mice. The GIR required to maintain euglycemia was higher in 18-heCcompared with 5-heCfasted mice at the end of the clamp (Fig. 4B and Table 4). GIR differences were not due to an effect on endoRa, because it was similarly suppressed in 18-heCand 5-heCfasted mice (Table 4). Instead, Rd was higher in 18-heCcompared with 5-heCfasted mice (Table 4). Glycolytic rates were also higher in 18-heCcompared with 5-heCfasted mice (Table 4). Given the lower Rd in 5-heCfasted mice, glycolysis as the percent of Rd was not different between groups (51 ± 3 vs. 47 ± 5% Rd in 5-heCand 18-heCfasted mice, respectively).
Comparison of insulin delivery methods.
Given the marked difference in insulin primes used in clamp studies, two general approaches for insulin priming were compared. Insulin clamps were performed on 5-heCfasted mice using a 16- or 300-mU/kg insulin prime. All samples were acquired from an arterial catheter. Clamp insulin levels were higher in mice receiving the 300-mU/kg prime compared with those receiving the 16-mU/kg prime (Table 4). Arterial glucose was clamped at similar levels in both groups (Fig. 5A). The GIR required to maintain euglycemia was stable throughout the clamp using the 16-mU/kg insulin prime (Fig. 5B). In contrast, clamps using the 300- mU/kg prime required a higher GIR to maintain euglycemia during the first 50 min of the clamp compared with clamps using the 16-mU/kg prime. The GIR decreased after the 300-mU/kg prime so that rates were not different between groups by the end of the clamp (Fig. 5B and Table 4). However, when results were normalized for the different clamp insulin levels in both groups, whole-body insulin sensitivity (GIR/clamp insulin) was higher in mice clamped with the 16-mU/kg prime compared with those clamped with the 300-mU/kg prime. EndoRa was fully suppressed in clamps using the 16-mU/kg prime but not in clamps using the 300-mU/kg prime. Conversely, Rd was higher after the 300-mU/kg compared with after the 16- mU/kg prime. Glycolytic rates were not different in clamps performed with either insulin prime, but because of the differences in Rd, glycolysis as the percent of Rd was higher after the 16- compared with the 300-mU/kg prime (47 ± 3 vs. 36 ± 2% Rd).
An 18-h fast caused several notable differences in the response to the larger insulin prime. In contrast to the higher clamp insulin levels in 5-heCfasted mice after the 300- compared with the 16-mU/kg insulin prime, the magnitude of the insulin prime had no effect on clamp insulin in 18-heCfasted mice (Table 4). Arterial glucose was similar in both groups (Fig. 6A). Unlike clamps in the 5-heCfasted mice, in 18-heCfasted mice the GIR was quickly stabilized after the 300-mU/kg prime so that it was not higher at the beginning than at the end of the clamp (Fig. 6B). The GIR was lower during the 1st h after the 16-mU/kg prime but rose so that the GIR at the end of the clamp was not different between groups (Fig. 6B). There was no significant difference in endoRa, Rd, or glycolytic rates between groups (Table 4).
To determine the effect of different doses of insulin, 5-heCfasted mice were clamped using constant insulin infusions of 0.8, 2.5, 4, or 20 mU · kgeC1 · mineC1. Arterial glucose was clamped at similar levels in all four groups (Fig. 7A), although levels were slightly lower in mice clamped with 2.5 mU · kgeC1 · mineC1. GIR and Rd rose with increasing doses of infused insulin (Fig. 7B and Table 5). EndoRa was not suppressed in mice clamped with 0.8 mU · kgeC1 · mineC1 but was equally suppressed in mice clamped with 2.5, 4, or 20 mU · kgeC1 · mineC1 (Table 5).
DISCUSSION
Despite increased use of the insulin clamp in assessing insulin action in mice, the lack of assessment of protocols used makes interpretation of results difficult and comparison between laboratories impossible. This is not a trivial issue, as many laboratories use insulin clamp protocols that differ from one another and from procedures used in human studies in both technical and conceptual aspects. Thus, in our studies, we systematically compared commonly used experimental variables in protocols for clamping conscious mice.
A key distinction between clamp protocols is the degree of mouse handling due to the manner of blood sample acquisition. Blood sampling from the cut tail in restrained mice requires manual squeezing of the tail. Previous studies have shown that handling of rodents markedly increases their circulating levels of catecholamines (37). In the studies presented here, cut taileCsampled mice exhibited elevated catecholamines compared with artery-sampled mice, indicating that cut tail sampling can be stressful (Fig. 1), although not as stressful as other forms of rodent handling (37). Catecholamine levels were not elevated in restrained mice with cut tails where blood for catecholamine analysis was obtained from an artery and only small volumes (5 e蘬) were obtained from the cut tail (Fig. 1). Because blood from the cut tail does not often flow freely, the tail must be manually squeezed several times to obtain large blood samples (100 e蘬), resulting in elevated catecholamines. Thus, the cut tail method is a viable technique if stress is not a concern of the study or if the sample volume needed is small (5 e蘬). Basal glucose levels were higher in cut taileCcompared with artery-sampled mice, resulting in lower initial GIR (Fig. 2A). This may be due, at least in part, to the inhibitory effect of epinephrine on insulin-stimulated muscle glucose uptake (38). During the clamp, suppression of endoRa was less, whereas stimulation of Rd was greater, in cut taileCcompared with artery-sampled mice, resulting in similar clamp GIR. An advantage of the cut tail method is the need for the less-invasive implantation of a single catheter. In these studies, this resulted in a 15% higher success rate (recovery from surgery, working catheter) compared with the double catheterization required for arterial sampling, although success rates will vary among surgeons.
In the present studies, insulin action was enhanced in 18-heCcompared with 5-heCfasted mice. This effect of fasting on insulin action has been previously reported in normal (39) and genetically modified (28,40) mice. Ren et al. (40) demonstrated that overexpression of the GLUT4 glucose transporter did not improve insulin-stimulated glucose disappearance in 3- to 4-heCfasted mice but did improve it in overnight-fasted mice. Halseth et al. (28) showed that the rate of muscle glucose uptake was enhanced in 18-heCcompared with 5-heCfasted mice overexpressing hexokinase II. Many factors may play a role in the modulation of insulin sensitivity by fasting duration. Prolonged lowering of insulin, as with an overnight fast, has been shown to enhance insulin sensitivity in humans (41). In our studies, the higher hepatic glycogen content in 5-heCcompared with 18-heCfasted mice might have contributed to the difference in clamp endoRa after the 300-mU/kg insulin prime (Table 4). Gastrocnemius glycogen content was not different between 5-heCand 18-heCfasted mice (Table 2). However, the possibility that glycogen content was reduced in other muscles in 18-heCcompared with 5-heCfasted mice cannot be ruled out. A variety of behavioral and physiological adaptations in mice, including increased appetite and spontaneous light cycle activity, reduced metabolic rate, torpor, and decreased heart rate and blood pressure, can also occur after a single overnight fast (42). We observed that overnight fasting resulted in a significant decrease in body weight, attributed to a loss of lean body mass (Table 2). Thus, at clamp onset, 18-heCfasted mice are in a catabolic state compared with their 5-heCfasted counterparts. In summary, prolonged food deprivation results in a metabolic state that enhances insulin action during a clamp. As demonstrated by the GLUT4 (40) and hexokinase II (28) overexpression studies, phenotypes can be appreciably altered by fasting duration, although this effect may depend on the model used.
Given the large disparity in insulin-priming strategies used in clamp studies, we were interested in determining how the magnitude of the priming dose would affect glucoregulation throughout the clamp. A prime is typically used to quickly raise the concentration to target steady-state levels. Assuming insulin clearance and Vd are not affected by fasting duration, the 16-mU/kg prime was calculated to reach a theoretical peak insulin concentration of 80 e蘒/ml. The prime used in many clamps using a 2.5-mU · kgeC1 · mineC1 insulin infusion is 300 mU/kg (1eC3), which is equal to the amount of insulin infused by the end of the clamp. This prime was calculated to raise the insulin concentration to a theoretical peak of 1,600 e蘒/ml. Previous studies have shown that Rd is maximal at plasma insulin of 200eC300 e蘒/ml in dogs and humans (43eC45). This may explain the rapid stabilization of GIR in studies using the 300- compared with the 16-mU/kg prime in 18-heCfasted mice (Fig. 6B). As described below, other factors can modulate the glucoregulatory effects of different insulin primes.
In contrast to the results with 18-heCfasted mice, the GIR was quickly stabilized after the 16- compared with the 300- mU/kg insulin prime in 5-heCfasted mice (Fig. 5B). Furthermore, although the magnitude of the prime had no effect on the GIR at the end of the clamp, the GIR normalized for insulin concentration (i.e., whole-body insulin sensitivity) was higher in 5-heCfasted mice clamped after the 16- compared with the 300-mU/kg prime. EndoRa was completely suppressed in 5-heCfasted mice after the 16- but not the 300-mU/kg prime, even though insulin at the end of the clamp was higher after the 300-mU/kg prime. These effects of the prime on insulin sensitivity and concentration were not observed in 18-heCfasted mice. It is possible that suprapharmacological insulin levels caused by the 300-mU/kg prime in combination with a factor specific to 5-heCfasted mice (e.g., substrate availability, activation status of signaling proteins) resulted in an impairment of insulin clearance and hepatic insulin action. We clearly cannot rule out the possibility that the insulin prime exerted persistent effects on other factors that were not measured.
Different doses of insulin can be constantly infused to differentiate hepatic effects from peripheral effects of insulin. In the present studies, endoRa was not suppressed with an insulin infusion of 0.8 mU · kgeC1 · mineC1 but was fully suppressed with infusions of 2.5, 4, and 20 mU · kgeC1 · mineC1 (Table 5). By contrast, the GIR and Rd rose with increasing infusions of insulin (Table 5). These results indicate that an insulin dose of 0.8eC2.5 mU · kgeC1 · mineC1 is required for specific targeting of hepatic effects in the mouse, whereas doses >2.5 mU · kgeC1 · mineC1 can be chosen depending on the anticipated magnitude and hypothesized effects of insulin in peripheral tissues.
One additional methodological difference in published clamp protocols requires consideration. It is typical for the tracer prime to be administered at the onset of the tracer- equilibration period and then followed by a continuous tracer infusion. However, a number of clamp studies performed in the mouse use a modified tracer method in which a large tracer prime (10 e藽i) is given not before tracer equilibration but at the onset of the clamp (2,4eC6,26,27,46eC52). This is a reasonable strategy if one assumes that the insulin prime at clamp onset results in a marked expansion of the glucose pool (i.e., accumulation of intracellular glucose). Clamp endoRa and Rd in those studies were similar to those presented here in equally fasted mice (18 h) using the same insulin prime (300 mU/kg). However, glycolytic rates were higher (69 ± 3% Rd) in those studies than in studies using the traditional tracer method (45 ± 2% Rd). It is likely that the large tracer prime at clamp onset results in a high rate of 3H2O appearance and thus an elevated measurement of glycolytic rate.
The studies presented here compared several commonly used approaches to performing clamps in the mouse. By systematically evaluating individual clamp parameters, we have demonstrated that experimental variables affect results obtained with this technique. These effects are observed at different times throughout the clamp. Thus, the standard practice of reporting data as an experimental average does not always provide a thorough description of the events occurring throughout the entire clamp. A search of publications in which the insulin clamp was used in mice also shows a disturbing trend toward neither describing nor citing a reference that describes how experiments are performed. The results of the present studies show that this is a serious deficit, making comparisons of results from different laboratories impossible. It is also reasonable to suggest that genetic manipulations and strain differences may modulate the degree to which certain experimental parameters influence clamp results. Thus, the effects observed in wild-type mice may be masked or enhanced in transgenic mice (28,40) or mice of different strains. Because of these factors, it is necessary that time course changes in glucose and GIR be given as well as descriptions of how clamps are performed so that results obtained from this very powerful technique can be fully used.
ACKNOWLEDGMENTS
This work was supported by U24-DK-59637 and RO1-DK-50277.
We thank the members of the NIDDK Mouse Metabolic Phenotyping Center Consortium (Yale University, University of Cincinnati, and University of Texas Southwestern) and its executive committee for their helpful input during the course of these studies. We also thank Angela Slater, Eric Allen, and Wanda Snead of the Vanderbilt Hormone Assay Core for performing the insulin and catecholamine assays. We thank Patrick T. Fueger for his contributions to these studies.
REFERENCES
Chen M, Haluzik M, Wolf NJ, Lorenzo J, Dietz KR, Reitman ML, Weinstein LS: Increased insulin sensitivity in paternal Gnas knockout mice is associated with increased lipid clearance. Endocrinology 145:4094eC4102, 2004
Haluzik M, Gavrilova O, LeRoith D: Peroxisome proliferator-activated receptor-alpha deficiency does not alter insulin sensitivity in mice maintained on regular or high-fat diet: hyperinsulinemic-euglycemic clamp studies. Endocrinology 145:1662eC1667, 2004
Heron-Milhavet L, Haluzik M, Yakar S, Gavrilova O, Pack S, Jou WC, Ibrahimi A, Kim H, Hunt D, Yau D, Asghar Z, Joseph J, Wheeler MB, Abumrad NA, LeRoith D: Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice. Endocrinology 145:4667eC4676, 2004
Kim JK, Fillmore JJ, Gavrilova O, Chao L, Higashimori T, Choi H, Kim HJ, Yu C, Chen Y, Qu X, Haluzik M, Reitman ML, Shulman GI: Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes 52:1311eC1318, 2003
Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S, Stannard B, Heron-Milhavet L, Wheeler MB, LeRoith D: Peroxisome proliferatoreCactivated receptor- agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52:1770eC1778, 2003
Spurlin BA, Thomas RM, Nevins AK, Kim HJ, Kim YJ, Noh HL, Shulman GI, Kim JK, Thurmond DC: Insulin resistance in tetracycline-repressible Munc18c transgenic mice. Diabetes 52:1910eC1917, 2003
Kim JK, Fillmore JJ, Sunshine MJ, Albrecht B, Higashimori T, Kim DW, Liu ZX, Soos TJ, Cline GW, O’Brien WR, Littman DR, Shulman GI: PKC- knockout mice are protected from fat-induced insulin resistance. J Clin Invest 114:823eC827, 2004
Cook S, Hugli O, Egli M, Menard B, Thalmann S, Sartori C, Perrin C, Nicod P, Thorens B, Vollenweider P, Scherrer U, Burcelin R: Partial gene deletion of endothelial nitric oxide synthase predisposes to exaggerated high-fat dieteCinduced insulin resistance and arterial hypertension. Diabetes 53:2067eC2072, 2004
Rangwala SM, Rhoades B, Shapiro JS, Rich AS, Kim JK, Shulman GI, Kaestner KH, Lazar MA: Genetic modulation of PPAR- phosphorylation regulates insulin sensitivity. Dev Cell 5:657eC663, 2003
Rangwala SM, Rich AS, Rhoades B, Shapiro JS, Obici S, Rossetti L, Lazar MA: Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 53:1937eC1941, 2004
Ahren B, Pacini G, Wynick D, Wierup N, Sundler F: Loss-of-function mutation of the galanin gene is associated with perturbed islet function in mice. Endocrinology 145:3190eC3196, 2004
Haluzik M, Colombo C, Gavrilova O, Chua S, Wolf N, Chen M, Stannard B, Dietz KR, Le Roith D, Reitman ML: Genetic background (C57BL/6J versus FVB/N) strongly influences the severity of diabetes and insulin resistance in ob/ob mice. Endocrinology 145:3258eC3264, 2004
Zabolotny JM, Haj FG, Kim YB, Kim HJ, Shulman GI, Kim JK, Neel BG, Kahn BB: Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action. J Biol Chem 279:24844eC24851, 2004
Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, Kim JK: Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060eC1067, 2004
Cariou B, Postic C, Boudou P, Burcelin R, Kahn CR, Girard J, Burnol AF, Mauvais-Jarvis F: Cellular and molecular mechanisms of adipose tissue plasticity in muscle insulin receptor knockout mice. Endocrinology 145:1926eC1932, 2004
Kim JK, Gimeno RE, Higashimori T, Kim HJ, Choi H, Punreddy S, Mozell RL, Tan G, Stricker-Krongrad A, Hirsch DJ, Fillmore JJ, Liu ZX, Dong J, Cline G, Stahl A, Lodish HF, Shulman GI: Inactivation of fatty acid transport protein 1 prevents fat-induced insulin resistance in skeletal muscle. J Clin Invest 113:756eC763, 2004
Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, Vaughan DE, Fogo AB: Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53:336eC346, 2004
Fueger PT, Bracy DP, Malabanan CM, Pencek RR, Granner DK, Wasserman DH: Hexokinase II overexpression improves exercise-stimulated but not insulin-stimulated muscle glucose uptake in high-fateCfed C57BL/6J mice. Diabetes 53:306eC314, 2004
Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M, Nawrocki AR, Rajala MW, Parlow AF, Cheeseboro L, Ding YY, Russell RG, Lindemann D, Hartley A, Baker GR, Obici S, Deshaies Y, Ludgate M, Rossetti L, Scherer PE: A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145:367eC383, 2004
Yakar S, Setser J, Zhao H, Stannard B, Haluzik M, Glatt V, Bouxsein ML, Kopchick JJ, LeRoith D: Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest 113:96eC105, 2004
Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Wilkes J, Evans RM, Olefsky J: Muscle-specific PPAR deletion causes insulin resistance. Nat Med 9:1491eC1497, 2003
Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingstrom G, Larsson C, Forsgren M, Ashkzari M, Nilsson CE, Fiedler M, Bergqvist E, Ohman B, Bjorkstrand E, Abrahmsen LB: Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144:4755eC4762, 2003
Fisher SJ, Kahn CR: Insulin signaling is required for insulin’s direct and indirect action on hepatic glucose production. J Clin Invest 111:463eC468, 2003
Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, Spiegelman BM, Kahn CR: Muscle-specific PPAR-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 112:608eC618, 2003
Viollet B, Andreelli F, Jorgensen SB, Perrin C, Geloen A, Flamez D, Mu J, Lenzner C, Baud O, Bennoun M, Gomas E, Nicolas G, Wojtaszewski JF, Kahn A, Carling D, Schuit FC, Birnbaum MJ, Richter EA, Burcelin R, Vaulont S: The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest 111:91eC98, 2003
Kim JK, Gavrilova O, Chen Y, Reitman ML, Shulman GI: Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem 275:8456eC8460, 2000
Kim JK, Michael MD, Previs SF, Peroni OD, Mauvais-Jarvis F, Neschen S, Kahn BB, Kahn CR, Shulman GI: Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. J Clin Invest 105:1791eC1797, 2000
Halseth AE, Bracy DP, Wasserman DH: Overexpression of hexokinase II increases insulin and exercise-stimulated muscle glucose uptake in vivo. Am J Physiol 276:E70eCE77, 1999
Niswender KD, Shiota M, Postic C, Cherrington AD, Magnuson MA: Effects of increased glucokinase gene copy number on glucose homeostasis and hepatic glucose metabolism. J Biol Chem 272:22570eC22575, 1997
Chan TM, Exton JH: A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. Anal Biochem 71:96eC105, 1976
Sherwin RS, Kramer KJ, Tobin JD, Insel PA, Liljenquist JE, Berman M, Andres R: A model of the kinetics of insulin in man. J Clin Invest 53:1481eC1492, 1974
Morgan CR, Lazarow A: Immunoassay of pancreatic and plasma insulin following alloxan injection of rats. Diabetes 14:669eC671, 1965
Macdonald IA, Lake DM: An improved technique for extracting catecholamines from body fluids. J Neurosci Methods 13:239eC248, 1985
Altszuler N, De Bodo RC, Steele R, Wall JS: Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187:15eC24, 1956
Clodi M, Thomaseth K, Pacini G, Hermann K, Kautzky-Willer A, Waldhusl W, Prager R, Ludvik B: Distribution and kinetics of amylin in humans. Am J Physiol 274:E903eCE908, 1998
Kobayashi K, Ota A, Togari A, Morita S, Mizuguchi T, Sawada H, Yamada K, Nagatsu I, Matsumoto S, Fujita K, et al: Alteration of catecholamine phenotype in transgenic mice influences expression of adrenergic receptor subtypes. J Neurochem 65:492eC501, 1995
Balcombe JP, Barnard ND, Sandusky C: Laboratory routines cause animal stress. Contemp Top Lab Anim Sci 43:42eC51, 2004
Han XX, Bonen A: Epinephrine translocates GLUT-4 but inhibits insulin-stimulated glucose transport in rat muscle. Am J Physiol 274:E700eCE707, 1998
Heijboer AC, Donga E, Voshol PJ, Dang ZC, Havekes LM, Romijn JA, Corssmit EP: Sixteen hours fasting differentially affects hepatic and muscle insulin sensitivity in mice. J Lipid Res 46:582eC588, 2004
Ren JM, Marshall BA, Mueckler MM, McCaleb M, Amatruda JM, Shulman GI: Overexpression of GLUT4 protein in muscle increases basal and insulin-stimulated whole body glucose disposal in conscious mice. J Clin Invest 95:429eC432, 1995
Vogt C, Petrides AS: Stimulation of muscle glucose disposal by insulin in humans is a function of the preexisting plasma insulin level. Am J Physiol 268:E1031eCE1038, 1995
Overton JM, Williams TD: Behavioral and physiologic responses to caloric restriction in mice. Physiol Behav 81:749eC754, 2004
Yang YJ, Hope I, Ader M, Poulin RA, Bergman RN: Dose-response relationship between lymph insulin and glucose uptake reveals enhanced insulin sensitivity of peripheral tissues. Diabetes 41:241eC253, 1992
Rizza RA, Mandarino LJ, Gerich JE: Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol 240:E630eCE639, 1981
Getty L, Hamilton-Wessler M, Ader M, Dea MK, Bergman RN: Biphasic insulin secretion during intravenous glucose tolerance test promotes optimal interstitial insulin profile. Diabetes 47:1941eC1947, 1998
Abel ED, Peroni O, Kim JK, Kim YB, Boss O, Hadro E, Minnemann T, Shulman GI, Kahn BB: Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409:729eC733, 2001
Fernandez AM, Kim JK, Yakar S, Dupont J, Hernandez-Sanchez C, Castle AL, Filmore J, Shulman GI, Le Roith D: Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 15:1926eC1934, 2001
Haluzik M, Dietz KR, Kim JK, Marcus-Samuels B, Shulman GI, Gavrilova O, Reitman ML: Adrenalectomy improves diabetes in A-ZIP/F-1 lipoatrophic mice by increasing both liver and muscle insulin sensitivity. Diabetes 51:2113eC2118, 2002
Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, Lutz EP, Kako Y, Velez-Carrasco W, Goldberg IJ, Breslow JL, Shulman GI: Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 98:7522eC7527, 2001
Kim JK, Zisman A, Fillmore JJ, Peroni OD, Kotani K, Perret P, Zong H, Dong J, Kahn CR, Kahn BB, Shulman GI: Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. J Clin Invest 108:153eC160, 2001
Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI: Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 108:437eC446, 2001
Yang C, Coker KJ, Kim JK, Mora S, Thurmond DC, Davis AC, Yang B, Williamson RA, Shulman GI, Pessin JE: Syntaxin 4 heterozygous knockout mice develop muscle insulin resistance. J Clin Invest 107:1311eC1318, 2001(Julio E. Ayala, Deanna P.)
Key Words: GIR, glucose infusion rate
ABSTRACT
Despite increased use of the hyperinsulinemic-euglycemic clamp to study insulin action in mice, the effects of experimental parameters on the results obtained have not been addressed. In our studies, we determined the influences of sampling sites, fasting duration, and insulin delivery on results obtained from clamps in conscious mice. Carotid artery and jugular vein catheters were implanted in C57BL/6J mice (n = 6eC10/group) fed a normal diet for sampling and infusions. After a 5-day recovery period, mice underwent a 120-min clamp (2.5-mU · kgeC1 · mineC1 insulin infusion; 120eC130 mg/dl glucose) while receiving [3-3H]glucose to determine glucose appearance (endoRa) and disappearance (Rd). Sampling large volumes (100 e蘬) from the cut tail resulted in elevated catecholamines and basal glucose compared with artery sampling. Catecholamines were not elevated when taking small samples ( 5 e蘬) from the cut tail. Overnight (18-h) fasting resulted in greater loss of total body, lean, and fat masses and hepatic glycogen but resulted in enhanced insulin sensitivity compared with 5-h fasting. Compared with a 16-mU/kg insulin prime, a 300-mU/kg prime resulted in hepatic insulin resistance and slower acquisition of steady-state glucose infusion rates (GIR) after a 5-h fast. The steady-state GIR was expedited after the 300-mU/kg prime in 18-heCfasted mice. The GIR and Rd rose with increasing insulin infusions (0.8, 2.5, 4, and 20 mU · kgeC1 · mineC1), but endoRa was fully suppressed with doses higher than 0.8 mU · kgeC1 · mineC1. Thus, common variations in experimental factors yield different results and should be considered in designing and interpreting clamps.
The hyperinsulinemic-euglycemic clamp, or insulin clamp, has been referred to as the "gold standard" for measuring insulin sensitivity in vivo. In this procedure, insulin is administered to raise the insulin concentration while glucose is infused to maintain euglycemia. The glucose infusion rate (GIR) needed to maintain euglycemia is a reflection of insulin action. When radioisotopes, such as [3H]glucose, are infused in conjunction with an insulin clamp, endogenous glucose appearance (endoRa) and glucose disappearance (Rd) can be measured, allowing for the differentiation between hepatic and peripheral insulin sensitivity. Given the prominent role of insulin resistance in the development of various metabolic disorders, the insulin clamp is a useful tool in basic and clinical research.
With the development of transgenic technologies in the mouse, the miniaturization of the insulin clamp for use in this animal has been an important advancement. It is thus surprising that in the >10 years since its first use in the mouse, there has been no assessment of the insulin clamp methodology in this animal. A literature search for the period 2003eC2004 found 25 publications using the insulin clamp in conscious mice (1eC25). In these studies, the various protocols that were used differed in blood sampling sites, insulin and tracer infusion methods, and fasting duration. For example, 44% of these studies described the sampling site as the cut tail, whereas 12% used an arterial catheter. The remaining 44% did not indicate or reference a study indicating a sampling site. In a similar finding, 48% of these studies used mice fasted overnight (for 16eC18 h), 40% used mice fasted for 5eC6 h, and 12% used other fasting durations. Finally, 40% of these clamp studies were performed without a priming dose of insulin, whereas 48% administered a prime equal to the total insulin infused at a constant rate. The remaining 12% used priming doses ranging between these two extremes. Given this diversity of approaches, it is crucial to determine how experimental parameters influence clamp studies in the mouse to better compare results obtained by different investigators. Using common clamp protocols as guidelines (18,26eC28), three parameters were compared: blood sampling sites, fasting duration, and insulin infusion (prime and constant rate) methods.
RESEARCH DESIGN AND METHODS
All procedures were approved by the Vanderbilt Animal Care and Use Committee. Male, 8-week-old C57BL/6J mice (The Jackson Laboratories, Bar Harbor, ME) were obtained and placed on a sterilized rodent diet (Harlan Teklad LM-485, #7912; Harlan Teklad, Madison, WI) for 1 week before surgery. Animals were housed under controlled temperature (23°C) and lighting (12 h light:12 h dark) conditions with free access to water and food.
Mice (n = 95) were catheterized at least 5 days before the experiments (29) after being anesthetized with sodium pentobarbital (70 mg/kg body wt). The left common carotid artery was catheterized for sampling using a two-part catheter consisting of PE-10 (inserted into the artery) and silastic (0.025 outer diameter [OD]). The right jugular vein was catheterized for infusions with a silastic catheter (0.025 OD). The free catheter ends were tunneled under the skin to the back of the neck and attached via stainless steel connectors to tubing made of Micro-Renathane (0.033 OD); the tubing was externalized and sealed with stainless steel plugs. In a subset of mice, only a jugular vein catheter was implanted (see COMPARISON OF SAMPLING SITES [below]). Lines were flushed daily with 50 e蘬 saline containing 200 units/ml heparin and 5 mg/ml ampicillin. Animals were individually housed after surgery, and their body weight was recorded daily. Animals not within 10% of their presurgery weight by postsurgery day 5 were excluded from the study.
Hyperinsulinemic-euglycemic clamps.
This section describes the general protocol used in all experiments. Modifications are described where appropriate in the following sections.
After being fasted for 5 or 18 h, mice were studied in individual 1.4-l plastic containers with bedding or a restrainer (552-BSRR; Plas-Labs, Lansing, MI) for cut tail sampling. The protocol consisted of a 120-min tracer equilibration period (t = eC120 to 0 min) beginning at 8:00 A.M. followed by a 120-min experimental period (t = 0 to 120 min) beginning at 10:00 A.M. A blood sample (5 e蘬) was obtained at t = eC120 min to determine initial glucose levels (HemoCue Meter; HemoCue, Lake Forest, CA). A 5-e藽i bolus of [3-3H]glucose purified by high-performance liquid chromatography was given at t = eC120 min followed by a 0.05 e藽i/ min infusion for 2 h. At t = eC5 min, a blood sample (100 e蘬) was taken for the assessment of basal glucose and insulin levels and glucose turnover. The insulin clamp was begun at t = 0 min with a primed-continuous infusion of human insulin (16 or 300 mU/kg bolus followed by 2.5 mU · kgeC1 · mineC1; Humulin R; Eli Lilly, Indianapolis, IN). The [3-3H]glucose infusion was increased to 0.1 e藽i/ min for the remainder of the experiment to minimize changes in specific activity from the equilibration period. Specific activity for individual time points did not vary by >15% from the average specific activity during the last 40 min of the clamp, and the slope of specific activity over time was not significantly different from zero. Euglycemia (120eC130 mg/dl) was maintained during clamps by measuring blood glucose every 10 min starting at t = 0 min and infusing 20% dextrose as necessary. Blood samples (60eC200 e蘬) were taken every 10 min from t = 80 to 120 min and processed to determine glucose specific activity. Clamp insulin levels were determined from samples obtained at t = 100 and 120 min. Additional samples (100 e蘬) were taken at t = eC120, eC5, and 120 min for the assessment of catecholamines. Mice received saline-washed erythrocytes from donors throughout the experimental period (5eC6 e蘬/min) to prevent a fall of >5% hematocrit.
Comparison of sampling sites.
In these studies, 18-heCfasted mice were compared using a 300-mU/kg insulin prime. For cut tail sampling, mice were surgically prepared with only a jugular vein catheter. The tip of the tail (1 cm) was cut off at t = eC120 min in restrained animals, and blood was sampled by squeezing the tail from base to tip. Samples obtained from the cut tail are composed of arterial and venous blood as well as lymph fluid. For arterial sampling, the externalized catheters were tethered to a stainless steel swivel (Instech Laboratories, Plymouth Meeting, PA) with Micro-Renathane tubing. This approach eliminated the need for restraining or any further handling of the mouse. In some studies, samples were obtained from both the cut tail and an arterial catheter in restrained mice.
Comparison of fasting duration.
Arterial catheters were used for sampling in these experiments. For the 5-heCfasting studies, food was removed at 5:00 A.M. on the day of the experiment, and for the 18-heCfasting studies, food was removed at 4:00 P.M. on the day before the experiment. Thus, all insulin infusions began at 10:00 A.M. Clamps followed a 16-mU/kg insulin prime. Body composition was determined in 5-heCand 18-heCfasted mice using a mq10 NMR analyzer (Bruker Optics, The Woodlands, TX). Liver and gastrocnemius muscle glycogen was determined as previously described (30). Food consumption was determined using a precision scale and continuous computer monitoring.
Comparison of insulin delivery methods.
Arterial catheters were used for sampling in these experiments. In one set of experiments, the insulin prime was 16 mU/kg. This dose was calculated as the amount of insulin required to fill the distribution volume (Vd) to the target clamp concentration (80 e蘒/ml). Insulin Vd was assumed to be 20% of body weight, an approximation based on the observed insulin Vd in humans (15.6% body wt) and the approximate plasma and interstitial fluid volume (25% body wt) (31). In a second set of experiments, the insulin prime was 300 mU/kg (1eC3). This is equal to the amount of insulin administered during the 120-min infusion. Assuming equal insulin clearance and Vd, the theoretical peak plasma insulin concentrations were 80 and 1,600 e蘒/ml with the 16- and 300-mU/kg boluses, respectively. Clamps were performed on 5-heCand 18-heCfasted mice.
For the insulin dose-response studies, clamps were performed on 5-heCfasted mice using constant insulin infusions of 0.8, 2.5, 4, or 20 mU · kgeC1 · mineC1.
Processing of plasma samples.
Plasma for [3-3H]glucose determinations was deproteinized with Ba(OH)2 and ZnSO4. For each sample, an aliquot of the supernatant was counted directly and another was dried to remove 3H2O. Plasma 3H2O was determined as the difference between dried and undried samples. Immunoreactive insulin (32) and catecholamines (33) were determined as previously described.
Calculations.
Ra and Rd were determined using Steele’s noneCsteady-state equations (34). Endogenous glucose production (endoRa, given as milligrams per kilogram per minute) was determined by subtracting the GIR from total Ra. Glycolytic rates were estimated from the increment per unit of time of 3H2O multiplied by the estimated body water divided by [3-3H]glucose specific activity. 3H2O appearance was determined by linear regression of the measurements at t = 80 to 120 min. Body water was assumed as 60% of body weight (35).
Statistical analysis.
Data are presented as means ± SE. Differences between groups were determined by two-way ANOVA followed by Tukey’s post hoc tests or by the t test, as appropriate. The significance level was P < 0.05.
RESULTS
Comparison of sampling sites.
Of the insulin clamp studies in the mouse published in 2003eC2004, 56% specified how blood was obtained. In most of these (80%), samples were obtained from the cut tail. We compared insulin clamps where the blood was obtained from the cut tail with those in which blood was obtained from an indwelling catheter. As shown in Fig. 1, epinephrine and norepinephrine were elevated in cut taileCcompared with artery-sampled mice throughout the study. This is consistent with previous reports of catecholamines in mice where blood was acquired from the cut tail (36). These elevated catecholamines were not due to mouse restraint or tail cutting. Restrained mice that had their tails cut off but were sampled from the artery showed catecholamine levels similar to those in unrestrained, artery-sampled mice (Fig. 1). The elevated catecholamines in the cut taileCsampled group were due to stress from the acquisition of the blood volume (100 e蘬) required for hormone assessment, which necessitates more manual squeezing of the tail than for smaller blood volumes. In mice sampled from both the artery and cut tail (Fig. 1), the larger volume of blood needed for catecholamine analysis was obtained from the artery, thus requiring less handling than when large samples were taken from the cut tail. The blood volume taken from the cut tail in these mice was 5 e蘬.
Basal glucose was significantly higher in cut taileCcompared with artery-sampled mice (Fig. 2A). This was not due to differences in arterial and cut tail glucose, because concentrations were similar in blood from both sites (Fig. 2A, inset). During clamps, blood glucose was similar in both groups (Fig. 2A). Because of the higher basal glucose in cut taileCsampled mice, the GIR required to clamp glucose in these mice was significantly lower for the first 20 min of the clamp compared with artery-sampled mice (Fig. 2B). The GIR was not different in cut taileCcompared with artery-sampled mice during the remainder of the experiment (Fig. 2B). Clamp endoRa was significantly higher in cut taileCcompared with artery-sampled mice (Table 1). However, clamp Rd was also significantly higher in cut taileCcompared with artery-sampled mice (Table 1), thus maintaining similar GIR between groups during the clamp.
Comparison of fasting duration.
The effects of fasting duration on the results from insulin clamps were investigated given the equal distribution of recent studies using 5-heCor 18-heCfasted mice. Because mice are primarily nocturnal feeders, an 18-h overnight fast represents a proportionately larger deprivation of calories. Mice consume 30% of their daily food intake during the daytime (Fig. 3). Thus, mice are already in a low-consumption mode when an 18-h fast is started (27). The subsequent overnight fast in our studies resulted in a significant loss of body weight (5 vs. 16% in 5-heCand 18-heCfasted mice, respectively) due to a reduction in fat and muscle tissue (Table 2). Overnight fasting also resulted in significantly lower hepatic, but not muscle, glycogen content (Table 2).
Basal glucose and insulin were lower in 18-heCcompared with 5-heCfasted mice (Table 3). Clamps were performed using a 16-mU/kg insulin prime, and samples were obtained from an arterial catheter. Clamp insulin levels were not different between groups (Table 4). Blood glucose fell in 18-heCcompared with 5-heCfasted mice during the first 40 min of the clamp, after which glucose was similar in both groups (Fig. 4A). The lower initial glucose levels and difficulty in maintaining euglycemia in 18-heCfasted mice was due to a delay in compensating for the increased insulin sensitivity in these mice. The GIR required to maintain euglycemia was higher in 18-heCcompared with 5-heCfasted mice at the end of the clamp (Fig. 4B and Table 4). GIR differences were not due to an effect on endoRa, because it was similarly suppressed in 18-heCand 5-heCfasted mice (Table 4). Instead, Rd was higher in 18-heCcompared with 5-heCfasted mice (Table 4). Glycolytic rates were also higher in 18-heCcompared with 5-heCfasted mice (Table 4). Given the lower Rd in 5-heCfasted mice, glycolysis as the percent of Rd was not different between groups (51 ± 3 vs. 47 ± 5% Rd in 5-heCand 18-heCfasted mice, respectively).
Comparison of insulin delivery methods.
Given the marked difference in insulin primes used in clamp studies, two general approaches for insulin priming were compared. Insulin clamps were performed on 5-heCfasted mice using a 16- or 300-mU/kg insulin prime. All samples were acquired from an arterial catheter. Clamp insulin levels were higher in mice receiving the 300-mU/kg prime compared with those receiving the 16-mU/kg prime (Table 4). Arterial glucose was clamped at similar levels in both groups (Fig. 5A). The GIR required to maintain euglycemia was stable throughout the clamp using the 16-mU/kg insulin prime (Fig. 5B). In contrast, clamps using the 300- mU/kg prime required a higher GIR to maintain euglycemia during the first 50 min of the clamp compared with clamps using the 16-mU/kg prime. The GIR decreased after the 300-mU/kg prime so that rates were not different between groups by the end of the clamp (Fig. 5B and Table 4). However, when results were normalized for the different clamp insulin levels in both groups, whole-body insulin sensitivity (GIR/clamp insulin) was higher in mice clamped with the 16-mU/kg prime compared with those clamped with the 300-mU/kg prime. EndoRa was fully suppressed in clamps using the 16-mU/kg prime but not in clamps using the 300-mU/kg prime. Conversely, Rd was higher after the 300-mU/kg compared with after the 16- mU/kg prime. Glycolytic rates were not different in clamps performed with either insulin prime, but because of the differences in Rd, glycolysis as the percent of Rd was higher after the 16- compared with the 300-mU/kg prime (47 ± 3 vs. 36 ± 2% Rd).
An 18-h fast caused several notable differences in the response to the larger insulin prime. In contrast to the higher clamp insulin levels in 5-heCfasted mice after the 300- compared with the 16-mU/kg insulin prime, the magnitude of the insulin prime had no effect on clamp insulin in 18-heCfasted mice (Table 4). Arterial glucose was similar in both groups (Fig. 6A). Unlike clamps in the 5-heCfasted mice, in 18-heCfasted mice the GIR was quickly stabilized after the 300-mU/kg prime so that it was not higher at the beginning than at the end of the clamp (Fig. 6B). The GIR was lower during the 1st h after the 16-mU/kg prime but rose so that the GIR at the end of the clamp was not different between groups (Fig. 6B). There was no significant difference in endoRa, Rd, or glycolytic rates between groups (Table 4).
To determine the effect of different doses of insulin, 5-heCfasted mice were clamped using constant insulin infusions of 0.8, 2.5, 4, or 20 mU · kgeC1 · mineC1. Arterial glucose was clamped at similar levels in all four groups (Fig. 7A), although levels were slightly lower in mice clamped with 2.5 mU · kgeC1 · mineC1. GIR and Rd rose with increasing doses of infused insulin (Fig. 7B and Table 5). EndoRa was not suppressed in mice clamped with 0.8 mU · kgeC1 · mineC1 but was equally suppressed in mice clamped with 2.5, 4, or 20 mU · kgeC1 · mineC1 (Table 5).
DISCUSSION
Despite increased use of the insulin clamp in assessing insulin action in mice, the lack of assessment of protocols used makes interpretation of results difficult and comparison between laboratories impossible. This is not a trivial issue, as many laboratories use insulin clamp protocols that differ from one another and from procedures used in human studies in both technical and conceptual aspects. Thus, in our studies, we systematically compared commonly used experimental variables in protocols for clamping conscious mice.
A key distinction between clamp protocols is the degree of mouse handling due to the manner of blood sample acquisition. Blood sampling from the cut tail in restrained mice requires manual squeezing of the tail. Previous studies have shown that handling of rodents markedly increases their circulating levels of catecholamines (37). In the studies presented here, cut taileCsampled mice exhibited elevated catecholamines compared with artery-sampled mice, indicating that cut tail sampling can be stressful (Fig. 1), although not as stressful as other forms of rodent handling (37). Catecholamine levels were not elevated in restrained mice with cut tails where blood for catecholamine analysis was obtained from an artery and only small volumes (5 e蘬) were obtained from the cut tail (Fig. 1). Because blood from the cut tail does not often flow freely, the tail must be manually squeezed several times to obtain large blood samples (100 e蘬), resulting in elevated catecholamines. Thus, the cut tail method is a viable technique if stress is not a concern of the study or if the sample volume needed is small (5 e蘬). Basal glucose levels were higher in cut taileCcompared with artery-sampled mice, resulting in lower initial GIR (Fig. 2A). This may be due, at least in part, to the inhibitory effect of epinephrine on insulin-stimulated muscle glucose uptake (38). During the clamp, suppression of endoRa was less, whereas stimulation of Rd was greater, in cut taileCcompared with artery-sampled mice, resulting in similar clamp GIR. An advantage of the cut tail method is the need for the less-invasive implantation of a single catheter. In these studies, this resulted in a 15% higher success rate (recovery from surgery, working catheter) compared with the double catheterization required for arterial sampling, although success rates will vary among surgeons.
In the present studies, insulin action was enhanced in 18-heCcompared with 5-heCfasted mice. This effect of fasting on insulin action has been previously reported in normal (39) and genetically modified (28,40) mice. Ren et al. (40) demonstrated that overexpression of the GLUT4 glucose transporter did not improve insulin-stimulated glucose disappearance in 3- to 4-heCfasted mice but did improve it in overnight-fasted mice. Halseth et al. (28) showed that the rate of muscle glucose uptake was enhanced in 18-heCcompared with 5-heCfasted mice overexpressing hexokinase II. Many factors may play a role in the modulation of insulin sensitivity by fasting duration. Prolonged lowering of insulin, as with an overnight fast, has been shown to enhance insulin sensitivity in humans (41). In our studies, the higher hepatic glycogen content in 5-heCcompared with 18-heCfasted mice might have contributed to the difference in clamp endoRa after the 300-mU/kg insulin prime (Table 4). Gastrocnemius glycogen content was not different between 5-heCand 18-heCfasted mice (Table 2). However, the possibility that glycogen content was reduced in other muscles in 18-heCcompared with 5-heCfasted mice cannot be ruled out. A variety of behavioral and physiological adaptations in mice, including increased appetite and spontaneous light cycle activity, reduced metabolic rate, torpor, and decreased heart rate and blood pressure, can also occur after a single overnight fast (42). We observed that overnight fasting resulted in a significant decrease in body weight, attributed to a loss of lean body mass (Table 2). Thus, at clamp onset, 18-heCfasted mice are in a catabolic state compared with their 5-heCfasted counterparts. In summary, prolonged food deprivation results in a metabolic state that enhances insulin action during a clamp. As demonstrated by the GLUT4 (40) and hexokinase II (28) overexpression studies, phenotypes can be appreciably altered by fasting duration, although this effect may depend on the model used.
Given the large disparity in insulin-priming strategies used in clamp studies, we were interested in determining how the magnitude of the priming dose would affect glucoregulation throughout the clamp. A prime is typically used to quickly raise the concentration to target steady-state levels. Assuming insulin clearance and Vd are not affected by fasting duration, the 16-mU/kg prime was calculated to reach a theoretical peak insulin concentration of 80 e蘒/ml. The prime used in many clamps using a 2.5-mU · kgeC1 · mineC1 insulin infusion is 300 mU/kg (1eC3), which is equal to the amount of insulin infused by the end of the clamp. This prime was calculated to raise the insulin concentration to a theoretical peak of 1,600 e蘒/ml. Previous studies have shown that Rd is maximal at plasma insulin of 200eC300 e蘒/ml in dogs and humans (43eC45). This may explain the rapid stabilization of GIR in studies using the 300- compared with the 16-mU/kg prime in 18-heCfasted mice (Fig. 6B). As described below, other factors can modulate the glucoregulatory effects of different insulin primes.
In contrast to the results with 18-heCfasted mice, the GIR was quickly stabilized after the 16- compared with the 300- mU/kg insulin prime in 5-heCfasted mice (Fig. 5B). Furthermore, although the magnitude of the prime had no effect on the GIR at the end of the clamp, the GIR normalized for insulin concentration (i.e., whole-body insulin sensitivity) was higher in 5-heCfasted mice clamped after the 16- compared with the 300-mU/kg prime. EndoRa was completely suppressed in 5-heCfasted mice after the 16- but not the 300-mU/kg prime, even though insulin at the end of the clamp was higher after the 300-mU/kg prime. These effects of the prime on insulin sensitivity and concentration were not observed in 18-heCfasted mice. It is possible that suprapharmacological insulin levels caused by the 300-mU/kg prime in combination with a factor specific to 5-heCfasted mice (e.g., substrate availability, activation status of signaling proteins) resulted in an impairment of insulin clearance and hepatic insulin action. We clearly cannot rule out the possibility that the insulin prime exerted persistent effects on other factors that were not measured.
Different doses of insulin can be constantly infused to differentiate hepatic effects from peripheral effects of insulin. In the present studies, endoRa was not suppressed with an insulin infusion of 0.8 mU · kgeC1 · mineC1 but was fully suppressed with infusions of 2.5, 4, and 20 mU · kgeC1 · mineC1 (Table 5). By contrast, the GIR and Rd rose with increasing infusions of insulin (Table 5). These results indicate that an insulin dose of 0.8eC2.5 mU · kgeC1 · mineC1 is required for specific targeting of hepatic effects in the mouse, whereas doses >2.5 mU · kgeC1 · mineC1 can be chosen depending on the anticipated magnitude and hypothesized effects of insulin in peripheral tissues.
One additional methodological difference in published clamp protocols requires consideration. It is typical for the tracer prime to be administered at the onset of the tracer- equilibration period and then followed by a continuous tracer infusion. However, a number of clamp studies performed in the mouse use a modified tracer method in which a large tracer prime (10 e藽i) is given not before tracer equilibration but at the onset of the clamp (2,4eC6,26,27,46eC52). This is a reasonable strategy if one assumes that the insulin prime at clamp onset results in a marked expansion of the glucose pool (i.e., accumulation of intracellular glucose). Clamp endoRa and Rd in those studies were similar to those presented here in equally fasted mice (18 h) using the same insulin prime (300 mU/kg). However, glycolytic rates were higher (69 ± 3% Rd) in those studies than in studies using the traditional tracer method (45 ± 2% Rd). It is likely that the large tracer prime at clamp onset results in a high rate of 3H2O appearance and thus an elevated measurement of glycolytic rate.
The studies presented here compared several commonly used approaches to performing clamps in the mouse. By systematically evaluating individual clamp parameters, we have demonstrated that experimental variables affect results obtained with this technique. These effects are observed at different times throughout the clamp. Thus, the standard practice of reporting data as an experimental average does not always provide a thorough description of the events occurring throughout the entire clamp. A search of publications in which the insulin clamp was used in mice also shows a disturbing trend toward neither describing nor citing a reference that describes how experiments are performed. The results of the present studies show that this is a serious deficit, making comparisons of results from different laboratories impossible. It is also reasonable to suggest that genetic manipulations and strain differences may modulate the degree to which certain experimental parameters influence clamp results. Thus, the effects observed in wild-type mice may be masked or enhanced in transgenic mice (28,40) or mice of different strains. Because of these factors, it is necessary that time course changes in glucose and GIR be given as well as descriptions of how clamps are performed so that results obtained from this very powerful technique can be fully used.
ACKNOWLEDGMENTS
This work was supported by U24-DK-59637 and RO1-DK-50277.
We thank the members of the NIDDK Mouse Metabolic Phenotyping Center Consortium (Yale University, University of Cincinnati, and University of Texas Southwestern) and its executive committee for their helpful input during the course of these studies. We also thank Angela Slater, Eric Allen, and Wanda Snead of the Vanderbilt Hormone Assay Core for performing the insulin and catecholamine assays. We thank Patrick T. Fueger for his contributions to these studies.
REFERENCES
Chen M, Haluzik M, Wolf NJ, Lorenzo J, Dietz KR, Reitman ML, Weinstein LS: Increased insulin sensitivity in paternal Gnas knockout mice is associated with increased lipid clearance. Endocrinology 145:4094eC4102, 2004
Haluzik M, Gavrilova O, LeRoith D: Peroxisome proliferator-activated receptor-alpha deficiency does not alter insulin sensitivity in mice maintained on regular or high-fat diet: hyperinsulinemic-euglycemic clamp studies. Endocrinology 145:1662eC1667, 2004
Heron-Milhavet L, Haluzik M, Yakar S, Gavrilova O, Pack S, Jou WC, Ibrahimi A, Kim H, Hunt D, Yau D, Asghar Z, Joseph J, Wheeler MB, Abumrad NA, LeRoith D: Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice. Endocrinology 145:4667eC4676, 2004
Kim JK, Fillmore JJ, Gavrilova O, Chao L, Higashimori T, Choi H, Kim HJ, Yu C, Chen Y, Qu X, Haluzik M, Reitman ML, Shulman GI: Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes 52:1311eC1318, 2003
Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S, Stannard B, Heron-Milhavet L, Wheeler MB, LeRoith D: Peroxisome proliferatoreCactivated receptor- agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52:1770eC1778, 2003
Spurlin BA, Thomas RM, Nevins AK, Kim HJ, Kim YJ, Noh HL, Shulman GI, Kim JK, Thurmond DC: Insulin resistance in tetracycline-repressible Munc18c transgenic mice. Diabetes 52:1910eC1917, 2003
Kim JK, Fillmore JJ, Sunshine MJ, Albrecht B, Higashimori T, Kim DW, Liu ZX, Soos TJ, Cline GW, O’Brien WR, Littman DR, Shulman GI: PKC- knockout mice are protected from fat-induced insulin resistance. J Clin Invest 114:823eC827, 2004
Cook S, Hugli O, Egli M, Menard B, Thalmann S, Sartori C, Perrin C, Nicod P, Thorens B, Vollenweider P, Scherrer U, Burcelin R: Partial gene deletion of endothelial nitric oxide synthase predisposes to exaggerated high-fat dieteCinduced insulin resistance and arterial hypertension. Diabetes 53:2067eC2072, 2004
Rangwala SM, Rhoades B, Shapiro JS, Rich AS, Kim JK, Shulman GI, Kaestner KH, Lazar MA: Genetic modulation of PPAR- phosphorylation regulates insulin sensitivity. Dev Cell 5:657eC663, 2003
Rangwala SM, Rich AS, Rhoades B, Shapiro JS, Obici S, Rossetti L, Lazar MA: Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 53:1937eC1941, 2004
Ahren B, Pacini G, Wynick D, Wierup N, Sundler F: Loss-of-function mutation of the galanin gene is associated with perturbed islet function in mice. Endocrinology 145:3190eC3196, 2004
Haluzik M, Colombo C, Gavrilova O, Chua S, Wolf N, Chen M, Stannard B, Dietz KR, Le Roith D, Reitman ML: Genetic background (C57BL/6J versus FVB/N) strongly influences the severity of diabetes and insulin resistance in ob/ob mice. Endocrinology 145:3258eC3264, 2004
Zabolotny JM, Haj FG, Kim YB, Kim HJ, Shulman GI, Kim JK, Neel BG, Kahn BB: Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action. J Biol Chem 279:24844eC24851, 2004
Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, Kim JK: Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060eC1067, 2004
Cariou B, Postic C, Boudou P, Burcelin R, Kahn CR, Girard J, Burnol AF, Mauvais-Jarvis F: Cellular and molecular mechanisms of adipose tissue plasticity in muscle insulin receptor knockout mice. Endocrinology 145:1926eC1932, 2004
Kim JK, Gimeno RE, Higashimori T, Kim HJ, Choi H, Punreddy S, Mozell RL, Tan G, Stricker-Krongrad A, Hirsch DJ, Fillmore JJ, Liu ZX, Dong J, Cline G, Stahl A, Lodish HF, Shulman GI: Inactivation of fatty acid transport protein 1 prevents fat-induced insulin resistance in skeletal muscle. J Clin Invest 113:756eC763, 2004
Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, Vaughan DE, Fogo AB: Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53:336eC346, 2004
Fueger PT, Bracy DP, Malabanan CM, Pencek RR, Granner DK, Wasserman DH: Hexokinase II overexpression improves exercise-stimulated but not insulin-stimulated muscle glucose uptake in high-fateCfed C57BL/6J mice. Diabetes 53:306eC314, 2004
Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M, Nawrocki AR, Rajala MW, Parlow AF, Cheeseboro L, Ding YY, Russell RG, Lindemann D, Hartley A, Baker GR, Obici S, Deshaies Y, Ludgate M, Rossetti L, Scherer PE: A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145:367eC383, 2004
Yakar S, Setser J, Zhao H, Stannard B, Haluzik M, Glatt V, Bouxsein ML, Kopchick JJ, LeRoith D: Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest 113:96eC105, 2004
Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Wilkes J, Evans RM, Olefsky J: Muscle-specific PPAR deletion causes insulin resistance. Nat Med 9:1491eC1497, 2003
Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingstrom G, Larsson C, Forsgren M, Ashkzari M, Nilsson CE, Fiedler M, Bergqvist E, Ohman B, Bjorkstrand E, Abrahmsen LB: Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144:4755eC4762, 2003
Fisher SJ, Kahn CR: Insulin signaling is required for insulin’s direct and indirect action on hepatic glucose production. J Clin Invest 111:463eC468, 2003
Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, Spiegelman BM, Kahn CR: Muscle-specific PPAR-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 112:608eC618, 2003
Viollet B, Andreelli F, Jorgensen SB, Perrin C, Geloen A, Flamez D, Mu J, Lenzner C, Baud O, Bennoun M, Gomas E, Nicolas G, Wojtaszewski JF, Kahn A, Carling D, Schuit FC, Birnbaum MJ, Richter EA, Burcelin R, Vaulont S: The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest 111:91eC98, 2003
Kim JK, Gavrilova O, Chen Y, Reitman ML, Shulman GI: Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem 275:8456eC8460, 2000
Kim JK, Michael MD, Previs SF, Peroni OD, Mauvais-Jarvis F, Neschen S, Kahn BB, Kahn CR, Shulman GI: Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. J Clin Invest 105:1791eC1797, 2000
Halseth AE, Bracy DP, Wasserman DH: Overexpression of hexokinase II increases insulin and exercise-stimulated muscle glucose uptake in vivo. Am J Physiol 276:E70eCE77, 1999
Niswender KD, Shiota M, Postic C, Cherrington AD, Magnuson MA: Effects of increased glucokinase gene copy number on glucose homeostasis and hepatic glucose metabolism. J Biol Chem 272:22570eC22575, 1997
Chan TM, Exton JH: A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. Anal Biochem 71:96eC105, 1976
Sherwin RS, Kramer KJ, Tobin JD, Insel PA, Liljenquist JE, Berman M, Andres R: A model of the kinetics of insulin in man. J Clin Invest 53:1481eC1492, 1974
Morgan CR, Lazarow A: Immunoassay of pancreatic and plasma insulin following alloxan injection of rats. Diabetes 14:669eC671, 1965
Macdonald IA, Lake DM: An improved technique for extracting catecholamines from body fluids. J Neurosci Methods 13:239eC248, 1985
Altszuler N, De Bodo RC, Steele R, Wall JS: Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187:15eC24, 1956
Clodi M, Thomaseth K, Pacini G, Hermann K, Kautzky-Willer A, Waldhusl W, Prager R, Ludvik B: Distribution and kinetics of amylin in humans. Am J Physiol 274:E903eCE908, 1998
Kobayashi K, Ota A, Togari A, Morita S, Mizuguchi T, Sawada H, Yamada K, Nagatsu I, Matsumoto S, Fujita K, et al: Alteration of catecholamine phenotype in transgenic mice influences expression of adrenergic receptor subtypes. J Neurochem 65:492eC501, 1995
Balcombe JP, Barnard ND, Sandusky C: Laboratory routines cause animal stress. Contemp Top Lab Anim Sci 43:42eC51, 2004
Han XX, Bonen A: Epinephrine translocates GLUT-4 but inhibits insulin-stimulated glucose transport in rat muscle. Am J Physiol 274:E700eCE707, 1998
Heijboer AC, Donga E, Voshol PJ, Dang ZC, Havekes LM, Romijn JA, Corssmit EP: Sixteen hours fasting differentially affects hepatic and muscle insulin sensitivity in mice. J Lipid Res 46:582eC588, 2004
Ren JM, Marshall BA, Mueckler MM, McCaleb M, Amatruda JM, Shulman GI: Overexpression of GLUT4 protein in muscle increases basal and insulin-stimulated whole body glucose disposal in conscious mice. J Clin Invest 95:429eC432, 1995
Vogt C, Petrides AS: Stimulation of muscle glucose disposal by insulin in humans is a function of the preexisting plasma insulin level. Am J Physiol 268:E1031eCE1038, 1995
Overton JM, Williams TD: Behavioral and physiologic responses to caloric restriction in mice. Physiol Behav 81:749eC754, 2004
Yang YJ, Hope I, Ader M, Poulin RA, Bergman RN: Dose-response relationship between lymph insulin and glucose uptake reveals enhanced insulin sensitivity of peripheral tissues. Diabetes 41:241eC253, 1992
Rizza RA, Mandarino LJ, Gerich JE: Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol 240:E630eCE639, 1981
Getty L, Hamilton-Wessler M, Ader M, Dea MK, Bergman RN: Biphasic insulin secretion during intravenous glucose tolerance test promotes optimal interstitial insulin profile. Diabetes 47:1941eC1947, 1998
Abel ED, Peroni O, Kim JK, Kim YB, Boss O, Hadro E, Minnemann T, Shulman GI, Kahn BB: Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409:729eC733, 2001
Fernandez AM, Kim JK, Yakar S, Dupont J, Hernandez-Sanchez C, Castle AL, Filmore J, Shulman GI, Le Roith D: Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 15:1926eC1934, 2001
Haluzik M, Dietz KR, Kim JK, Marcus-Samuels B, Shulman GI, Gavrilova O, Reitman ML: Adrenalectomy improves diabetes in A-ZIP/F-1 lipoatrophic mice by increasing both liver and muscle insulin sensitivity. Diabetes 51:2113eC2118, 2002
Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, Lutz EP, Kako Y, Velez-Carrasco W, Goldberg IJ, Breslow JL, Shulman GI: Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 98:7522eC7527, 2001
Kim JK, Zisman A, Fillmore JJ, Peroni OD, Kotani K, Perret P, Zong H, Dong J, Kahn CR, Kahn BB, Shulman GI: Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. J Clin Invest 108:153eC160, 2001
Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI: Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 108:437eC446, 2001
Yang C, Coker KJ, Kim JK, Mora S, Thurmond DC, Davis AC, Yang B, Williamson RA, Shulman GI, Pessin JE: Syntaxin 4 heterozygous knockout mice develop muscle insulin resistance. J Clin Invest 107:1311eC1318, 2001(Julio E. Ayala, Deanna P.)